State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 ; volume:7 ; number:1 ; day:1 ; month:8 ; year:2019 ; pages:1-6 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (1.8.2019), 1-6, 12.2019
- Urheber
-
Lemal, Richard
Tournilhac, Olivier
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0686-x
- URN
-
urn:nbn:de:101:1-2019122602363744914683
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lemal, Richard
- Tournilhac, Olivier
- SpringerLink (Online service)
Ähnliche Objekte (12)
Evolving strategies for addressing CAR T-cell toxicities
CAR T-Cell therapy
Optimal CAR T-cell immunotherapy strategies for a leukemia treatment model
Recent advances in CAR T-cell therapy for lymphoma in China
CAR T-Cell therapy for the management of mantle cell lymphoma
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia
The CAR T‐Cell Mechanoimmunology at a Glance
CAR T-cell therapy and critical care : A survival guide for medical emergency teams
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Evolving strategies for addressing CAR T-cell toxicities
CAR T-Cell therapy
Optimal CAR T-cell immunotherapy strategies for a leukemia treatment model
Recent advances in CAR T-cell therapy for lymphoma in China
CAR T-Cell therapy for the management of mantle cell lymphoma
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia
The CAR T‐Cell Mechanoimmunology at a Glance
CAR T-cell therapy and critical care : A survival guide for medical emergency teams
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Evolving strategies for addressing CAR T-cell toxicities
CAR T-Cell therapy
Optimal CAR T-cell immunotherapy strategies for a leukemia treatment model
Recent advances in CAR T-cell therapy for lymphoma in China
CAR T-Cell therapy for the management of mantle cell lymphoma
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia
The CAR T‐Cell Mechanoimmunology at a Glance
CAR T-cell therapy and critical care : A survival guide for medical emergency teams